November 10, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Tim Buchmiller
Mr. Joseph McCann
RE: Nerium Biotechnology Inc.
Registration Statement on Form 10-12G
Filed: September 18, 2020
File No. 000-54051
Dear Sirs:
Nerium Biotechnology, Inc. (the "Company") hereby requests that the United States Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form 10-12G, as amended (File No. 000-54051), to become effective on Tuesday, November 10, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Company hereby authorizes its counsel, Arnold Zipper, Esq. of Cole Schotz P.C., to orally modify or withdraw this request for acceleration. Please contact Mr. Zipper at (561) 715-0364 with any questions you may have concerning this request, and please notify Mr. Zipper when this request for acceleration has been granted.
| Sincerely, | |
| / s / Dennis Knocke | |
| Dennis Knocke | |
| Chief Executive Officer |
